Novel agents for advanced pancreatic cancer

Akintunde Akinleye; Chaitanya Iragavarapu; Muhammad Furqan; Shundong Cang; Delong Liu

doi:10.18632/oncotarget.3999

Back

Novel agents for advanced pancreatic cancer

Journal article

Open access

Peer reviewed

Novel agents for advanced pancreatic cancer

Akintunde Akinleye, Chaitanya Iragavarapu, Muhammad Furqan, Shundong Cang and Delong Liu

Oncotarget, Vol.6(37), pp.39521-39537

11/24/2015

DOI: 10.18632/oncotarget.3999

PMCID: PMC4741843

PMID: 26369833

Files and links (1)

url

https://doi.org/10.18632/oncotarget.3999View

Published (Version of record) Open Access

Abstract

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.

Pancreatic Neoplasms - drug therapy

Pancreatic Neoplasms - metabolism

Signal Transduction - drug effects

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Humans

Small Molecule Libraries - therapeutic use

Survival Analysis

Immunoconjugates - therapeutic use

Antibodies, Monoclonal - therapeutic use

Treatment Outcome

Clinical Trials as Topic

Details

Title: Subtitle: Novel agents for advanced pancreatic cancer
Creators: Akintunde Akinleye - Division of Hematology/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States
Chaitanya Iragavarapu - Division of Hematology/Oncology, Department of Medicine, New York Medical College, Valhalla, New York, United States
Muhammad Furqan - Division of Hematology/Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa, United States
Shundong Cang - Department of Oncology, Henan Province People's Hospital, Zhengzhou University, Zhengzhou, China
Delong Liu - Department of Oncology, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Resource Type: Journal article
Publication Details: Oncotarget, Vol.6(37), pp.39521-39537
DOI: 10.18632/oncotarget.3999
PMID: 26369833
PMCID: PMC4741843
NLM abbreviation: Oncotarget
ISSN: 1949-2553
eISSN: 1949-2553
Language: English
Date published: 11/24/2015
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094380702771

Metrics

10 Record Views

28 Times Cited - Web of Science